ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering.
The Berlin-headquartered company, which counts billionaire investor Peter Thiel as one of its main backers, submitted an S-1 filing to the Securities and Exchange Commission on Tuesday.
The filing shows that ATAI has raised an aggregate of $362.3 million from private investors so far.
It is planning to sell its shares on New York’s tech-focused Nasdaq market under the symbol ATAI. A date for the IPO has not been set.
Underwriters for the IPO include Credit Suisse, Citigroup, Cowen, and Berenberg.
ATAI, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.
The company, which has roughly 50 staff in offices across Berlin, New York and San Diego, is currently partnered with 14 companies focusing on drug development and other technologies. In exchange for a majority stake in the drugs and technologies they’re developing, ATAI helps the scientists to raise money, work with the regulators, and conduct clinical trials. None of ATAI’s drugs have been formally approved by regulators to date.
Thiel made a 10 million euro ($12 million) investment in ATAI through his venture firm, Thiel Capital, in November.
“ATAI’s great virtue is to take mental illness as seriously as we should have been taking all illness all along,” Thiel, who co-founded Palantir and PayPal, said in a statement shared with CNBC at the time. “The company’s most valuable asset is its sense of urgency.”
The company was founded in 2018 by entrepreneurs Christian Angermayer, Florian Brand, Lars Wilde and Srinivas Rao. It has invested in Compass Pathways, which has developed a synthetic version of the active ingredient in magic mushrooms, psilocybin.
Compass Pathways, which Thiel has also invested in, listed on the New York’s NASDAQ stock exchange in September and now has a valuation of around $1.3 billion.
